8-K: EyePoint's DURAVYU Phase 3 Trials Receive Positive DSMC Recommendation

EyePoint announced a positive third consecutive recommendation from its Data Safety Monitoring Committee for the ongoing Phase 3 trials of DURAVYU in wet AMD, reinforcing confidence ahead of mid-2026 topline data.

Summary

• EyePoint, Inc. received a positive recommendation from the independent Data Safety Monitoring Committee (DSMC) following its third review of the ongoing pivotal Phase 3 program for DURAVYU, a treatment for wet age-related macular degeneration (wet AMD).
• The DSMC recommended that both the LUGANO and LUCIA trials continue as planned without any protocol modifications.
• As of May 2, 2026, all active patients in the treatment arm have reached the Week 32 visit, with over 35% having received their third planned dose at Week 56.
• Interim masked safety data show a continued favorable safety profile for DURAVYU, consistent with previous clinical trials involving over 190 patients.
• This is the last anticipated DSMC meeting before topline data is expected, which is on track for mid-2026 for the LUGANO trial, with the LUCIA readout to follow shortly after.
• The Phase 3 trials have enrolled over 900 patients, randomized 1:1 to receive DURAVYU every six months or on-label aflibercept.
• DURAVYU is an investigational sustained-delivery treatment combining vorolanib with Durasert E technology, designed for at least six months of sustained release.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, with the third consecutive positive DSMC recommendation significantly de-risking the Phase 3 program for DURAVYU and building confidence ahead of topline data.

Positives

• Third consecutive positive recommendation from the independent Data Safety Monitoring Committee (DSMC) for the Phase 3 wet AMD trials.
• DSMC recommended continuation of both LUGANO and LUCIA trials without protocol modifications.
• Favorable safety profile observed in interim masked Phase 3 data, consistent with four prior completed clinical trials.
• All active patients in the treatment arm have reached their second DURAVYU dosing visit, and over 35% have received their third planned dose.
• Enrollment is complete in both LUGANO and LUCIA trials with over 900 patients.
• DURAVYU is designed for sustained release for at least six months, potentially reducing treatment burden.
• The company has a history of developing and commercializing therapeutics for retinal diseases, with four approved drugs over three decades.

Negatives

• DURAVYU is an investigational product and has not been approved by the FDA; approval timeline is uncertain.
• The filing mentions a DOJ investigation and uncertainties related to a potential settlement and corporate integrity agreement.
• There are uncertainties regarding an FDA warning letter pertaining to the company's Watertown, MA manufacturing facility.

Risks

• Uncertainties and delays relating to communications with the U.S. Food and Drug Administration and the ability to obtain regulatory approval.
• The risk that results of clinical trials may not be predictive of future results, and interim data are subject to further analysis and may change.
• Unexpected safety or efficacy data observed during clinical trials.
• Changes in the regulatory environment and potential disruptions at the FDA.
• Delays, interruptions, or failures in the manufacture and supply of product candidates, including due to regulatory compliance issues or warning letters.
• The need for additional financing and the uncertainty of obtaining it.
• Potential impact of a DOJ investigation settlement and corporate integrity agreement on business operations.
• Uncertainties related to the FDA warning letter for the Watertown manufacturing facility.

Future Outlook

Topline data for the LUGANO Phase 3 trial is expected to be reported starting in mid-2026, with the LUCIA readout to follow shortly after. Data from the Phase 3 program for DURAVYU in Diabetic Macular Edema (DME) is anticipated in the second half of 2027. The company's cash runway is mentioned as a potential concern if additional funding is not secured.

Management Comments

• "Safety is paramount in retinal disease therapies, and receiving three consecutive positive DSMC recommendations to continue our Phase 3 wet AMD trials without modification reflects the consistency of DURAVYUs safety profile and the rigor of our Phase 3 wet AMD program design," said Ramiro Ribeiro, M.D., Ph.D., Chief Medical Officer at EyePoint.
• "This continued independent validation, together with the favorable safety profile observed across four completed clinical trials, reinforces our confidence as we approach Phase 3 topline data beginning in mid-2026."
• "If successful, we believe that DURAVYU is well-positioned to be a first and best-in-class therapy with the potential to establish a new treatment paradigm for patients who have long needed better options."

Industry Context

StockSavvy.ai notes that the positive DSMC recommendation for DURAVYU in wet AMD trials is a significant milestone in a competitive landscape. The sustained-release mechanism of DURAVYU, aiming for six-month dosing, addresses a key unmet need for reduced treatment burden compared to current standard-of-care anti-VEGF therapies that require more frequent injections.

Legal Proceedings

• The company is involved in a DOJ investigation, with uncertainties regarding the impact of a potential settlement and corporate integrity agreement.

Stakeholder Impact

• Shareholders: Positive news regarding the DURAVYU trial progress may increase confidence and potentially impact stock price, but risks related to FDA approval, manufacturing, and the DOJ investigation remain.
• Patients: Potential for a new treatment option (DURAVYU) with a reduced dosing frequency (every six months) for wet AMD, addressing a significant treatment burden.
• Healthcare System: A successful DURAVYU launch could lead to reduced healthcare costs associated with frequent treatments and improved patient compliance.

Next Steps

• Await topline data for the LUGANO and LUCIA Phase 3 wet AMD trials, expected to begin reporting in mid-2026.
• Continue Phase 3 trials for DURAVYU in Diabetic Macular Edema (DME) with data anticipated in the second half of 2027.
• Address ongoing DOJ investigation and potential settlement.
• Resolve issues related to the FDA warning letter for the Watertown manufacturing facility.

Key Dates

Recommendation

While the positive DSMC recommendation is encouraging and de-risks the DURAVYU program, significant uncertainties remain regarding FDA approval, manufacturing compliance (FDA warning letter), and the outcome of the DOJ investigation. These factors warrant a 'hold' recommendation until further clarity emerges on these critical issues.

Keywords

DURAVYU, wet AMD, Phase 3 trials, EyePoint, DSMC, retinal diseases, vorolanib, clinical trials